Your browser doesn't support javascript.
loading
Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk.
Eiholzer, Ramona A; Mehta, Sunali; Kazantseva, Marina; Drummond, Catherine J; McKinney, Cushla; Young, Katie; Slater, David; Morten, Brianna C; Avery-Kiejda, Kelly A; Lasham, Annette; Fleming, Nicholas; Morrin, Helen R; Reader, Karen; Royds, Janice A; Landmann, Michael; Petrich, Simone; Reddel, Roger; Huschtscha, Lily; Taha, Ahmad; Hung, Noelyn A; Slatter, Tania L; Braithwaite, Antony W.
Afiliação
  • Eiholzer RA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • Mehta S; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • Kazantseva M; Maurice Wilkins Centre for Molecular Biodiscovery, Dunedin 9016, New Zealand.
  • Drummond CJ; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • McKinney C; Maurice Wilkins Centre for Molecular Biodiscovery, Dunedin 9016, New Zealand.
  • Young K; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • Slater D; Maurice Wilkins Centre for Molecular Biodiscovery, Dunedin 9016, New Zealand.
  • Morten BC; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • Avery-Kiejda KA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • Lasham A; Priority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.
  • Fleming N; Hunter Medical Research Institute, New South Wales 2305, Australia.
  • Morrin HR; Priority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.
  • Reader K; Hunter Medical Research Institute, New South Wales 2305, Australia.
  • Royds JA; Priority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.
  • Landmann M; Hunter Medical Research Institute, New South Wales 2305, Australia.
  • Petrich S; Department of Molecular Medicine and Pathology, University of Auckland, Auckland 1023, New Zealand.
  • Reddel R; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • Huschtscha L; Department of Pathology and Biomedical Science, University of Otago, Christchurch 8140, New Zealand.
  • Taha A; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • Hung NA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
  • Slatter TL; Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
  • Braithwaite AW; Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Cancers (Basel) ; 12(9)2020 Sep 01.
Article em En | MEDLINE | ID: mdl-32882831
We investigated the influence of selected TP53 SNPs in exon 4 and intron 4 on cancer risk, clinicopathological features and expression of TP53 isoforms. The intron 4 SNPs were significantly over-represented in cohorts of mixed cancers compared to three ethnically matched controls, suggesting they confer increased cancer risk. Further analysis showed that heterozygosity at rs1042522(GC) and either of the two intronic SNPs rs9895829(TC) and rs2909430(AG) confer a 2.34-5.35-fold greater risk of developing cancer. These SNP combinations were found to be associated with shorter patient survival for glioblastoma and prostate cancer. Additionally, these SNPs were associated with tumor-promoting inflammation as evidenced by high levels of infiltrating immune cells and expression of the Δ133TP53 and TP53ß transcripts. We propose that these SNP combinations allow increased expression of the Δ133p53 isoforms to promote the recruitment of immune cells that create an immunosuppressive environment leading to cancer progression.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article